Mitsuhito Koizumi

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Yoichi Hiasa · 12 shared papers, 2013–2025 · strength 1.46
   • Paper Clinicopathological features for clinically resectable peripherally located pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2025.06.010↗
   • Paper Protein kinase R regulates pancreatic ductal adenocarcinoma progression by modulating the cell cycle via GADD45A. DOI 10.1038/s41598-025-06213-4↗
   • Paper A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable adva… DOI 10.1007/s10147-025-02717-1↗
2. Teru Kumagi · 11 shared papers, 2013–2025 · strength 1.22
   • Paper Protein kinase R regulates pancreatic ductal adenocarcinoma progression by modulating the cell cycle via GADD45A. DOI 10.1038/s41598-025-06213-4↗
   • Paper A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable adva… DOI 10.1007/s10147-025-02717-1↗
   • Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
3. Yoshinori Ohno · 8 shared papers, 2013–2025 · strength 0.95
   • Paper Clinicopathological features for clinically resectable peripherally located pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2025.06.010↗
   • Paper A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable adva… DOI 10.1007/s10147-025-02717-1↗
   • Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
4. Taira Kuroda · 7 shared papers, 2013–2025 · strength 0.70
   • Paper A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable adva… DOI 10.1007/s10147-025-02717-1↗
   • Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
   • Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
5. Ichinosuke Hyodo · 4 shared papers, 2021–2025 · strength 0.67
   • Paper Clinicopathological features for clinically resectable peripherally located pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2025.06.010↗
   • Paper A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable adva… DOI 10.1007/s10147-025-02717-1↗
   • Paper Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in U… DOI 10.2169/internalmedicine.8736-21↗
6. Yuki Numata · 3 shared papers, 2024–2025 · strength 0.66
   • Paper Refractory postoperative pancreatic fistula following laparoscopic distal pancreatectomy for pancreatic cancer caused b… DOI 10.1007/s12328-024-01942-x↗
   • Paper Protein kinase R regulates pancreatic ductal adenocarcinoma progression by modulating the cell cycle via GADD45A. DOI 10.1038/s41598-025-06213-4↗
   • Paper A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable adva… DOI 10.1007/s10147-025-02717-1↗
7. Takashi Terao · 6 shared papers, 2017–2023 · strength 0.59
   • Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
   • Paper Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in U… DOI 10.2169/internalmedicine.8736-21↗
   • Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
8. Akinori Asagi · 3 shared papers, 2022–2025 · strength 0.56
   • Paper Clinicopathological features for clinically resectable peripherally located pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2025.06.010↗
   • Paper A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable adva… DOI 10.1007/s10147-025-02717-1↗
   • Paper Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in U… DOI 10.2169/internalmedicine.8736-21↗
9. Nobuaki Azemoto · 7 shared papers, 2013–2023 · strength 0.54
   • Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
   • Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
   • Paper ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. DOI 10.2169/internalmedicine.3748-19↗
10. Yoshinori Tanaka · 6 shared papers, 2013–2023 · strength 0.50
    • Paper Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome … DOI 10.3390/cancers15030561↗
    • Paper Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer. DOI 10.1097/md.0000000000027591↗
    • Paper ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. DOI 10.2169/internalmedicine.3748-19↗
11. Toru Otsuru · 2 shared papers, 2025 · strength 0.45
    • Paper Clinicopathological features for clinically resectable peripherally located pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2025.06.010↗
    • Paper A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable adva… DOI 10.1007/s10147-025-02717-1↗
12. Kaori Hino · 2 shared papers, 2022–2025 · strength 0.32
    • Paper A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable adva… DOI 10.1007/s10147-025-02717-1↗
    • Paper Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in U… DOI 10.2169/internalmedicine.8736-21↗
13. Naotake Funamizu · 1 shared paper, 2024 · strength 0.24
    • Paper Refractory postoperative pancreatic fistula following laparoscopic distal pancreatectomy for pancreatic cancer caused b… DOI 10.1007/s12328-024-01942-x↗
14. Yasutsugu Takada · 1 shared paper, 2024 · strength 0.24
    • Paper Refractory postoperative pancreatic fistula following laparoscopic distal pancreatectomy for pancreatic cancer caused b… DOI 10.1007/s12328-024-01942-x↗
15. Hiroshi Ishii · 2 shared papers, 2019–2020 · strength 0.16
    • Paper ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. DOI 10.2169/internalmedicine.3748-19↗
    • Paper Early Detection of Pancreatic Cancer in Patients With Chronic Liver Disease Under Hepatocellular Carcinoma Surveillance. DOI 10.1016/j.mayocp.2018.12.034↗
16. Masanori Abe · 3 shared papers, 2013–2020 · strength 0.15
    • Paper ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. DOI 10.2169/internalmedicine.3748-19↗
    • Paper Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer. DOI 10.1371/journal.pone.0071367↗
    • Paper Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collabo… DOI 10.1186/1471-230x-13-134↗
17. Morikazu Onji · 2 shared papers, 2013 · strength 0.06
    • Paper Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer. DOI 10.1371/journal.pone.0071367↗
    • Paper Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collabo… DOI 10.1186/1471-230x-13-134↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.